Breast cancer:: from estrogen to androgen receptor

被引:120
|
作者
Andò, S
De Amicis, F
Rago, V
Carpino, A
Maggiolini, M
Panno, ML
Lanzino, M
机构
[1] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy
[2] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, CS, Italy
关键词
breast cancer; estrogen; androgen;
D O I
10.1016/S0303-7207(02)00105-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and postmenopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E-2. DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E-2 (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E-2 presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E-2 proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E-2 action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574 --> Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E-2 signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E-2. This seems to be related to the inhibitory effects of the over-expressed AR on E-2 genomic action. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [41] Estrogen receptor β in breast cancer
    Shoker B.
    Breast Cancer Research, 3 (1)
  • [42] Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies
    Venema, Clasina M.
    Mammatas, Lemonitsa H.
    Schroeder, Carolina P.
    van Kruchten, Michel
    Apollonio, Giulia
    Glaudemans, AndorW. J. M.
    Bongaerts, Alfons H. H.
    Hoekstra, Otto S.
    Verheul, Henkm. W.
    Boven, Epi
    van der Vegt, Bert
    de Vries, Erik F. J.
    de Vries, Elisabeth G. E.
    Boellaard, Ronald
    van Oordt, Catharina W. Menke van der Houven
    Hospers, Geke A. P.
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (12) : 1906 - 1912
  • [43] Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations
    Agoff, SN
    Swanson, PE
    Linden, H
    Hawes, SE
    Lawton, TJ
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (05) : 725 - 731
  • [44] Prognostic value of androgen receptor expression in premenopausal women with estrogen receptor-positive breast cancer
    Yildirim, H. C.
    Uner, M.
    Yildiran, T.
    Guven, D. C.
    Yilmaz, F.
    Yasar, S.
    Evlendi, Y. N.
    Dizdar, O.
    Uner, A.
    Aksoy, S.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1397 - S1397
  • [45] Clinical and immunohistochemical associations with androgen receptor expression in breast cancer, with an emphasis on estrogen receptor negative tumors
    Agoff, SN
    Swanson, PE
    Hawes, SE
    Lawton, TJ
    LABORATORY INVESTIGATION, 2003, 83 (01) : 20A - 21A
  • [46] Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer
    Xu, Feng
    Xu, Kun
    Fan, Lingling
    Li, Xintong
    Liu, Yiqiu
    Yang, Fang
    Zhu, Chengjun
    Guan, Xiaoxiang
    CHINESE MEDICAL JOURNAL, 2024, 137 (03) : 338 - 349
  • [47] Androgen receptor (AR) agonists inhibit AR- and estrogen-receptor-positive breast cancer
    Asemota, Sarah
    Ponnusamy, Suriyan
    Thiyagarajan, Thirumagal
    Narayanan, Ramesh
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Clinical and immunohistochemical associations with androgen receptor expression in breast cancer, with an emphasis on estrogen receptor negative tumors
    Agoff, SN
    Swanson, PE
    Hawes, SE
    Lawton, TJ
    MODERN PATHOLOGY, 2003, 16 (01) : 20A - 21A
  • [49] A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer
    Chia, Kee Ming
    Liu, Ji
    Francis, Glenn D.
    Naderi, Ali
    NEOPLASIA, 2011, 13 (02): : 154 - 166
  • [50] ANDROGEN RECEPTOR ACTIVITY IN HUMAN-BREAST CANCER AND ITS RELATIONSHIP WITH ESTROGEN AND PROGESTOGEN RECEPTOR ACTIVITY
    MILLER, WR
    TELFORD, J
    DIXON, JM
    HAWKINS, RA
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (04): : 539 - 542